Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size - A randomized controlled trial
Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size - A randomized controlled trial
复制标题
DOI：
10.1097/01.aog.0000243776.23391.7b
复制
发表时间：
2006-12-01
影响因子：
7.2
通讯作者：
Guzick, David S.
中科院分区：
文献类型：
--
作者：
Fiscella, Kevin;Eisinger, Steven H.;Guzick, David S.
目的：探讨小剂量米非司酮对症状性子宫肌瘤患者生活质量、疼痛、出血和子宫大小的影响。方法：42例子宫体积大于或等于160毫升的症状性子宫肌瘤患者随机分为米非司酮每日5 mg组和安慰剂组，疗程26周。在基线、治疗1个月、3个月和6个月时评估生活质量(子宫肌瘤症状生活质量问卷和医学结果研究36项简表调查)以及子宫和肌瘤大小(超声检查)。每月评估出血(每日记录和图表)和疼痛(McGill疼痛问卷)。在基线和6个月时评估子宫内膜病理。结果：42名妇女被随机分配；37名妇女完成了全部6个月。随机服用米非司酮的女性在子宫肌瘤特有的生活质量方面有所改善。41%的人闭经，贫血率改善，调整后的子宫大小减少了47%。与安慰剂组相比，治疗组对这些结果的改善明显(P
Objective: To assess the effect of low-dose mifepristone on quality of life, pain, bleeding, and uterine size among women with symptomatic leiomyomata.Methods: Forty-two women with symptomatic uterine leiomyomata and uterine volume of 160 mL or more were randomized to mifepristone, 5 mg daily, or placebo for 26 weeks. Quality of life (Uterine Fibroid Symptoms Quality of Life Questionnaire and Medical Outcomes Study 36-Item Short Form survey) and uterine and leiomyoma size (ultrasonography) were assessed at baseline, and at 1 month, 3 months, and 6 months of treatment. Bleeding (daily logs and pictorial charts) and pain (McGill Pain Questionnaire) were assessed monthly. Endometrial pathology was assessed at baseline and 6 months.Results: Forty-two women were randomized; 37 women completed all 6 months. Women randomized to mifepristone showed an improvement in leiomyoma-specific quality of life. Forty-one percent became amenorrheic, rates of anemia improved, and adjusted uterine size was reduced by 47%. Compared with the placebo group, improvements in these outcomes in the treatment group were significantly greater (P